Jack Higgins
Known title: Chief Scientific OfficerCIK: 0001993684
Associated companies
Transaction History
| IMNM | ▲ Buy | Option Exercise | 18,000 | $24K | 9/11/2026 | View on chart |
| IMNM | ▼ Sell | Open Market | 13,200 | $334K | 9/11/2026 | View on chart |
| IMNM | ▼ Sell | Gift | 8,800 | $0 | 9/11/2026 | View on chart |
| IMNM | ▲ Buy | Grant | 38,250 | $0 | 7/23/2026 | View on chart |
| IMNM | ▼ Sell | Open Market | 9,438 | $204K | 4/2/2026 | View on chart |
| IMNM | ▼ Sell | Gift | 6,291 | $0 | 3/30/2026 | View on chart |
| IMNM | ▼ Sell | Gift | 1,000 | $0 | 12/19/2025 | View on chart |
| IMNM | ▼ Sell | Gift | 1,000 | $0 | 12/19/2025 | View on chart |
| IMNM | ▼ Sell | Gift | 1,000 | $0 | 12/19/2025 | View on chart |
| IMNM | ▼ Sell | Gift | 1,000 | $0 | 12/19/2025 | View on chart |
| IMNM | ▼ Sell | Gift | 1,000 | $0 | 12/19/2025 | View on chart |
| IMNM | ▼ Sell | Gift | 1,000 | $0 | 12/19/2025 | View on chart |
| IMNM | ▲ Buy | Option Exercise | 22,000 | $30K | 9/10/2025 | View on chart |
| IMNM | ▲ Buy | Option Exercise | 5,200 | $7K | 3/27/2025 | View on chart |
| IMNM | ▼ Sell | Gift | 2,471 | $0 | 8/19/2024 | View on chart |
| IMNM | ▲ Buy | Option Exercise | 19,524 | $26K | 8/15/2024 | View on chart |
| IMNM | ▼ Sell | Open Market | 3,524 | $49K | 8/15/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Immunome files Nasdaq inducement grant report, sees higher volume
Immunome disclosed inducement grants in a filing required by Nasdaq Listing Rule 5635(c)(4). The disclosure shows the company is meeting reporting obligations for equity compensation. At the same time, the stock appeared among Benzinga’s recent volume movers, indicating a noticeable increase in trading activity. These items together suggest regulatory compliance and heightened market attention.
Immunome files Nasdaq inducement grant report, sees higher volume. Immunome disclosed inducement grants in a filing required by Nasdaq Listing Rule 5635(c)(4). The disclosure shows the company is meeting reporting obligations for equity compensation. At the same time, the stock appeared among Benzinga’s recent volume movers, indicating a noticeable increase in trading activity. These items together suggest regulatory compliance and heightened market attention.